Eurofins Discovery Publishes Groundbreaking Study Showcasing the Predictive Power of SAFETYscan47 for Drug Safety and Clinical Success
NEWS PROVIDED BY:
Eurofins Discovery
SAN DIEGO, CA – September 8, 2025 — Eurofins Discovery, an industry-leading provider of products and services for drug discovery announced today a publication in ACS Pharmacology & Translational Science Journal, titled “Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict Potential Safety Risks during Drug Development.”
This article highlights the utility of in vitro pharmacological profiling by comparing clinically failed drug candidates against a diverse compound data set. Through deeper evaluation of data generated with SAFETYscan®47, the publication demonstrates how in vitro profiling provides critical insights in preclinical discovery, enhancing patient safety and helping to reduce clinical attrition.
Access the full manuscript here: https://pubs.acs.org/doi/10.1021/acsptsci.5c00452?ref=pdf
For further information:
Verena Albert
Verena.Albert@discovery.eurofinsus.com
About Eurofins Discovery
Eurofins Discovery supports drug discovery research with over 23,000 products and services developed in 40+ years of industry leadership. Benefit from the strength of our solutions that revolutionize your drug discovery.
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
